AdipoGen BAFF/APRIL Biomarkers Advance Autoimmune Research

• Direct contact technical support
• Find products for your research

B cell survival and plasma cell maintenance are tightly controlled by the TNF superfamily ligands BAFF (BLyS/TNFSF13B) and APRIL (TNFSF13), making them cornerstone biomarkers for autoimmune disease research. AdipoGen’s dedicated portfolio targets this BAFF/APRIL axis with high-sensitivity ELISA kits, potent blocking antibodies, multimeric recombinant proteins, and decoy receptors, enabling precise detection and functional interrogation across a range of applications.

For quantification, AdipoGen offers multiple ELISAs, including the unique BAFF–APRIL (human) Heteromers ELISA, designed to detect trimeric heteromers produced in autoimmune settings—a highly specific biomarker readout not addressed by conventional single-analyte assays. The APRIL (human) ELISA and BAFF, Soluble (human) ELISA provide sensitive, specific measurement in serum, plasma, and supernatants, with newly developed mouse BAFF ELISA extending utility to in vivo models. Together, these assays help profile ligand abundance and complex formation across health and disease.

For mechanism-of-action studies, AdipoGen’s blocking antibodies enable selective pathway control. The anti-BAFF (mouse) mAb Sandy-2 is highly potent in vivo, functionally phenocopying BAFF deficiency. Complementing this, anti-APRIL (mouse) antibodies—Apry-1-1 and Centotto-1—block APRIL binding to BCMA/TACI and support combined BAFF/APRIL pathway inhibition in translational models. These tools have underpinned recent studies exploring BAFF/APRIL roles in inflammation, plasma cell maintenance, and novel disease models.

Activity matters: AdipoGen’s multimeric ligands (e.g., MultimericAPRIL constructs and BAFF 60-mer) mimic membrane-bound signaling and drive robust pathway activation, while decoy receptors (e.g., TACI:Fc, BCMA:Fc, BAFF-R:Fc) enable inhibition and capture assays. This combination supports comprehensive experimental design—from quantitation and neutralization to functional rescue—across immunology, rheumatology, and biomarker discovery workflows.

By making these specialized BAFF/APRIL tools available in the BeNeLux via Bio-Connect, we help researchers quantify disease-relevant heteromers, fine-tune pathway activity in vitro/in vivo, and accelerate translational insights for conditions such as SLE, Sjögren’s syndrome, IgA nephropathy, and rheumatoid arthritis.